TriangleIbrutinib + Indoximod (NCT05106296)
Ibrutinib + Indoximod trial for Pediatric Brain Cancer (NCT05106296). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for brain cancer in children and young adults, ages 3 to 25, that has progressed or not responded to treatment, including ependymoma, medulloblastoma and glioblastoma.
The idea: combine immune and chemotherapy drugs. Ibrutinib is added to indoximod with either cyclophosphamide and etoposide, or temozolomide, in cycles of at least 28 days. Patients need MRI confirmation of active disease.
This phase 1 study finds the best safe dose of ibrutinib, and plans 37 participants. At Augusta University in Georgia, Theodore Johnson leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.